Medicis Pharmaceutical Corp. (MRX) Tops Q2 EPS by 39c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MRX Hot Sheet
Price: $70.00 +2.37%
Revenue Growth %: +21.2%
Financial Fact:
Weighted Average Number Of Diluted Shares Outstanding: 58.33M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +21.2%
Financial Fact:
Weighted Average Number Of Diluted Shares Outstanding: 58.33M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Medicis Pharmaceutical Corp. (NASDAQ: MRX) reported Q2 EPS of $1.64, $0.39 better than the analyst estimate of $1.25. Revenue for the quarter came in at $695.8 million versus the consensus estimate of $595.88 million.
For earnings history and earnings-related data on Medicis Pharmaceutical Corp. (MRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Arm Holdings (ARM) Tops Q2 EPS by 5c, Beats on Revenue; Offers Q3 Guidance
- Lumen Technologies (LUMN) Misses Q3 EPS by 4c
- Cytokinetics (CYTK) Tops Q3 EPS by 8c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
